US · LPCN · BIOTECHNOLOGY
Lipocine Inc. (LPCN) intrinsic value and stock valuation
$1.48as of 2026-11-21 · Mkt cap 12.59M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Lipocine Inc. DCF and intrinsic value
InvestorsCraft values LPCN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LPCN’s statements →
Lipocine Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.98M | $11.2M | -$-2.85M | $500K | $16.1M |
| Operating income | -$-10.37M | -$-1.16M | -$-17.93M | -$-12.12M | $3.15M |
| Net income | -$-9.63M | $10K | -$-16.35M | -$-10.76M | -$-630K |
| EPSd | -$-1.69M | $1.85K | -$-3.1M | -$-2.05M | -$-122.33K |
| Operating cash flow | -$-9.76M | -$-1.22M | -$-11.87M | -$-11.97M | -$-4.41M |
| Capital expenditure | $0.00 | -$-90K | -$-10K | -$-130K | -$-10K |
| Free cash flow | -$-9.76M | -$-1.31M | -$-11.88M | -$-12.1M | -$-4.42M |
| Total assets | $17M | $22.5M | $23M | $37.5M | $52.5M |
| Total debt | $450K | $0.00 | $0.00 | $0.00 | $2.31M |
| Net debt | -$-4.76M | -$-6.21M | -$-4.77M | -$-3.15M | -$-640K |
| Total equity | $14.5M | $21M | $20.4M | $35.6M | $45.6M |
| Cash and short-term investments | $14.9M | $21.6M | $22M | $32.5M | $44.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.98M | $11.2M | -$-2.85M | $500K | $16.1M |
| Cost of revenue | $8.58M | $0.00 | $10.2M | $8.56M | $7.67M |
| Gross profit | -$-6.61M | $11.2M | -$-13.03M | -$-8.06M | $8.48M |
| Research and development expenses | $0.00 | $7.35M | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $3.76M | $5M | $4.9M | $4.06M | $5.33M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $3.76M | $12.4M | $4.9M | $4.06M | $5.33M |
| Cost and expenses | $12.4M | $12.4M | $15.1M | $12.6M | $13M |
| Interest income | $740K | $1.15M | $1.37M | $570K | $70K |
| Interest expense | $0.00 | $0.00 | $0.00 | $30K | $200K |
| Depreciation and amortization | $60K | $40K | $30K | $10K | $0.00 |
| Ebitda | -$-9.57M | $50K | -$-16.32M | -$-10.72M | -$-430K |
| Operating income | -$-10.37M | -$-1.16M | -$-17.93M | -$-12.12M | $3.15M |
| Total other income/expenses, net | $740K | $1.16M | $1.58M | $1.36M | -$-3.78M |
| Income before tax | -$-9.63M | $10K | -$-16.35M | -$-10.76M | -$-630K |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-9.63M | $10K | -$-16.35M | -$-10.76M | -$-630K |
| Weighted average shares outstanding | $5.45M | $5.34M | $5.27M | $4.99M | $3.3M |
| Weighted average diluted shares outstanding | $5.71M | $5.42M | $5.27M | $5.26M | $5.15M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $14.9M | $21.6M | $22M | $32.5M | $44.6M |
| Net receivables | $10K | $120K | $50K | $660K | $250K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $16.9M | $22.3M | $22.9M | $34.1M | $46.4M |
| Property, plant and equipment, net | $100K | $170K | $120K | $130K | $10K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $3.25M | $2.02M |
| Total non-current assets | $130K | $190K | $140K | $3.41M | $6.1M |
| Total assets | $17M | $22.5M | $23M | $37.5M | $52.5M |
| Accounts payable | $970K | $270K | $1.4M | $600K | $1.29M |
| Short-term debt | $450K | $0.00 | $0.00 | $0.00 | $2.31M |
| Deferred revenue | $0.00 | $320K | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $2.53M | $1.51M | $2.63M | $1.68M | $5.62M |
| Long-term debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $0.00 | $0.00 | $0.00 | $230K | $1.3M |
| Capital lease obligations | $450K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $2.53M | $1.51M | $2.63M | $1.91M | $6.91M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-209.4M | -$-199.77M | -$-199.78M | -$-183.43M | -$-172.67M |
| Accumulated other comprehensive income (loss) | $0.00 | $10K | $10K | -$-20K | -$-20K |
| Total equity | $14.5M | $21M | $20.4M | $35.6M | $45.6M |
| Total investments | $9.72M | $15.4M | $17.3M | $32.6M | $43.7M |
| Total debt | $450K | $0.00 | $0.00 | $0.00 | $2.31M |
| Net debt | -$-4.76M | -$-6.21M | -$-4.77M | -$-3.15M | -$-640K |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-9.63M | $10K | -$-16.35M | -$-10.76M | -$-630K |
| Depreciation and amortization | $60K | $40K | $30K | $10K | $0.00 |
| Stock-based compensation | $240K | $410K | $650K | $640K | $600K |
| Change in working capital | -$-240K | -$-960K | $2.01M | -$-920K | -$-4.59M |
| Accounts receivable | $110K | -$-70K | $740K | $380K | -$-250K |
| Inventory | $0.00 | $0.00 | $0.00 | -$-380K | $250K |
| Accounts payable | $700K | -$-1.12M | $800K | -$-690K | -$-310K |
| Net cash provided by operating activities | -$-9.76M | -$-1.22M | -$-11.87M | -$-11.97M | -$-4.41M |
| Investments in property, plant and equipment | $0.00 | -$-90K | -$-10K | -$-130K | -$-10K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-14.29M | $43.8B |
| Net cash used for investing activities | $5.89M | $2.45M | $13.1M | $14.3M | -$-43.78M |
| Common stock issued | $2.87M | $210K | $400K | $0.00 | $30.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | -$-20K | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $2.87M | $210K | $400K | -$-2.13M | $26.9M |
| Net change in cash | -$-1M | $1.43M | $1.62M | $200K | -$-21.27M |
| Cash at end of period | $5.21M | $6.21M | $4.77M | $3.15M | $2.95M |
| Operating cash flow | -$-9.76M | -$-1.22M | -$-11.87M | -$-11.97M | -$-4.41M |
| Capital expenditure | $0.00 | -$-90K | -$-10K | -$-130K | -$-10K |
| Free cash flow | -$-9.76M | -$-1.31M | -$-11.88M | -$-12.1M | -$-4.42M |
Line items
Line items
Line items
About Lipocine Inc.
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
- CEO
- Mahesh V. Patel
- Employees
- 14
- Beta
- 0.44
Explore
Frequently asked questions
What is the intrinsic value of Lipocine Inc. (LPCN)?
InvestorsCraft does not currently publish an intrinsic value for LPCN. How the IC value is calculated.
Is LPCN undervalued?
InvestorsCraft does not publish an undervaluation signal for LPCN at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.